Literature DB >> 24274658

Phenotypic, immunologic, and clinical characteristics of patients with nontuberculous mycobacterial lung disease in Korea.

Ae-Ra Lee1, Jinwoo Lee, Sun-Mi Choi, Moon-Woo Seong, Sung A Kim, Myoungsil Kim, Kyung Ok Chae, Ji Sun Lee, Jae-Joon Yim.   

Abstract

BACKGROUND: This study aimed to elucidate the phenotypic, immunologic, and clinical characteristics of Korean patients with nontuberculous mycobacterial (NTM) lung disease and compare them with non-NTM bronchiectasis (BE) patients.
METHODS: We prospectively recruited patients between 20 and 80 years of age who had nodular BE type NTM lung disease. Phenotypic, immunologic, and clinical characteristics were evaluated through physical examination, laboratory tests, pulmonary function tests, and radiographic examinations. Questionnaires were also answered. The results of the evaluations were compared with the results of non-NTM BE patients.
RESULTS: A total of 84 patients with NTM lung disease and 47 non-NTM BE patients participated in the study. Mycobacterium avium complex lung disease and M. abscessus lung disease were most common. Patients with NTM lung disease had lower body mass index than non-NTM BE patients. Scoliosis was observed more frequently in patients with NTM lung disease than in non-NTM BE patients.
CONCLUSIONS: Significant similarities were seen between Korean patients with NTM lung disease and patients from other countries. Differences in phenotypic and clinical characteristics between NTM lung disease and non-NTM BE patients suggest differences in the immunopathogenesis of NTM lung disease and non-NTM BE. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov Registration number; NCT01616745.

Entities:  

Mesh:

Year:  2013        PMID: 24274658      PMCID: PMC4222821          DOI: 10.1186/1471-2334-13-558

Source DB:  PubMed          Journal:  BMC Infect Dis        ISSN: 1471-2334            Impact factor:   3.090


Background

Nontuberculous mycobacteria (NTM) are environmentally ubiquitous organisms, and rarely cause disease in healthy individuals. Rates of NTM isolation, as well as the number of patients with NTM lung disease, have been increasing worldwide [1]; however, the fact that only a small number of people contract NTM despite ubiquitous exposure suggests the presence of identifiable risk factors associated with NTM infection. While the immunopathogenesis of NTM lung disease remains largely unknown, certain phenotypic and immunologic characteristics of patients with NTM lung disease have been observed. A single nucleotide polymorphism in TLR2 has been linked to NTM lung diseases [2], and IFN-γ and IL-10 secretions have been reported to be suppressed among patients with NTM lung disease [3]. Furthermore, patients with NTM lung disease tend to be taller and leaner on average, with relatively high frequencies of scoliosis, pectus excavatum, and mitral valve prolapse [4]. While the incidence of tuberculosis has been in steady decline across South Korea, the rate of NTM isolation has increased rapidly [5]. The aim of this study was to elucidate the phenotypic, immunologic, and clinical characteristics of Korean patients with NTM lung diseases through comparisons with non-NTM bronchiectasis (BE) patients.

Methods

Study cohort

Beginning July 1, 2011 we prospectively recruited patients between 20 and 80 years of age at Seoul National University Hospital, Seoul, South Korea, who met the diagnostic criteria for NTM lung disease set forth by the American Thoracic Society [6]. Patients previously treated for NTM lung disease were excluded from this study. NTM patients with nodular BE types were included but those with upper lobe cavitary types were excluded. All patients provided written informed consent before enrollment. The study protocol was approved by the Institutional Review Board of Seoul National University Hospital. The clinical trial registration number is NCT 01616745 (www.ClinicalTrials.gov).

Control group

Beginning January 1, 2012 we began recruiting patients ≥ 20 years old diagnosed with BE in the absence of NTM infection (non-NTM) to serve as a control group. BE was diagnosed based on low dose computed tomography (CT) findings that included dilatation of an airway lumen, rendering it more than 1.5 times the width of a nearby vessel, lack of tapering of an airway toward the periphery, varicose constrictions along airways, and ballooned cysts at the end of a bronchus [7]. Two separate sputum mycobacterial cultures were performed to exclude patients with active NTM infections. The median interval between the two cultures was 24 months (interquartile range: 9–55 months).

Physical examinations

Physical examinations were performed by board-certified physicians. Height and weight were measured by a team of two nurses.

Microbiological tests

Sputum was collected for bacterial and mycobacterial cultures. Samples of sputum were homogenized by incubation at 37°C for 15 min with an equal volume of 0.1% dithiothreitol (Sputolysin; Calbiochem Corp., San Diego, CA, USA). Homogenized sputum was sequentially diluted and placed in phosphate-buffered saline and plated on blood, chocolate, and MacConkey agar plates. Sputum isolates were classified as potential pathogens or as normal flora. Potential pathogens were Haemophilus influenzae, Moraxella catarrhalis, Streptococcus pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, and other gram-negative rods; other bacterial species were classified as normal flora [8]. Sputum and bronchial washing fluid were decontaminated with 4% sodium hydroxide, homogenized, and concentrated by centrifugation at 3000 × g for 20 min. The specimens were stained using the Ziehl–Nielsen method [6]. Concentrated specimens were cultured in 3% Ogawa medium and observed weekly for 9 weeks after inoculation. Following isolation of a suspected mycobacterial species, confirmation of NTM was performed by analyzing the sequences of three genes; 16S rRNA, rpoB and tuf. Polymerase chain reaction and subsequent sequencing were performed, and the resulting sequences were compared with the reference database using basic local alignment search tools. Mycobacterial species were identified using 16S rRNA sequences, using the algorithm described in Clinical and Laboratory Standards Institute guideline MM18-A [9].

Laboratory tests

Laboratory tests consisted of the following: leukocyte count including differential counts, hematocrit, hemoglobin, platelet count, total cholesterol, total protein, albumin, total and direct bilirubin, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, blood urea nitrogen, creatinine, electrolytes, erythrocyte sedimentation rate, C-reactive protein, fluorescent antinuclear antibody test (FANA), rheumatoid factor, serum immunoglobulins (IgG, IgA, IgM), and IFN-γ release assay (IGRA).

Pulmonary function tests and radiographic examination

Pulmonary function tests, including forced expiratory volume at 1 second (FEV1), forced vital capacity (FVC), FEV1/FVC ratio, and diffusing capacity (DLCO) were performed. Simple posterior–anterior chest radiography, paranasal sinus radiography, and CT of the chest were carried out. Radiographic findings on CT scans were evaluated with regard to the presence of cavitations, nodule, and bronchiectasis. The anatomical distributions were also analyzed. Lesions were classified as showing either upper lobe cavitary disease or nodular bronchiectatic disease by radiographic type. When the disease did not belong to either the upper lobe cavitary form or the nodular bronchiectatic form, it was categorized as unclassifiable. The extent of bronchiectasis was scored in each of the six lobes (right upper lobe, right middle lobe, right lower lobe, upper division of the left upper lobe, lingular division of the left upper lobe, left lower lobe) according to the proportion of lung involvement. Extent scores ranged from 0 to 18; 0 if < 25%, 1 if 25–49%, 2 if 50–74%, 3 if ≥ 75% [10]. Scoliosis was determined from the posterior–anterior chest radiograph. Pectus excavatum was determined from CT scans of the chest using the Haller index and defined as a Haller index greater than 3.5 [11].

Questionnaires

All participants were asked to complete the St. George’s respiratory questionnaire and Hospital Anxiety and Depression Scale (HADS) questionnaire. The HADS is a 14 item questionnaire measuring levels of anxiety (HADS-A, seven items) and depression (HADS-D, seven items). Each item is scored from 0–3; a cut-off point of 8 out of 21 is suggested for both the anxiety and depression sections [12].

Analysis

Baseline characteristics were summarized using descriptive statistics such as proportion, median, and interquartile range. Student’s t-tests and Mann–Whitney U-tests were used for comparison of continuous variables. Categorical variables were compared using chi-square or Fisher’s exact tests, as appropriate. A P-value of ≤ 0.05 was considered to indicate statistical significance. All statistical analyses were performed using SPSS 17.0 (SPSS Inc., Chicago, IL, USA).

Results

Patient characteristics

A total of 127 patients with NTM lung disease were enrolled in the study, with eight patients withdrawing consent prior to study completion. Among them, 84 patients with nodular BE type NTM lung disease were included in the study. In addition, 50 patients with non-NTM BE were initially enrolled in the study; three patients withdrew consent. The median ages were 67 and 64 years for NTM lung disease and non-NTM BE groups, respectively (P = 0.16). Of the patients with NTM lung disease, 54 (64.3%) were female, compared with 29 (61.7%) in the non-NTM BE group. Among comorbidities, cancer was more common among the NTM lung disease group (21.4% vs. 6.4%, P = 0.03) (Table 1). Weight loss was more common among the NTM lung disease group although it failed to reach the conventional P-value of 0.05. (15.5% vs. 4.3%, P = 0.08) (Table 1).
Table 1

Baseline characteristics of 84 patients with NTM lung disease and 47 non-NTM BE patients

 
NTM lung disease patients
Non-NTM BE patients
P value
 (N = 84)(N = 47) 
Age (year), median (IQR)
67 (57,75)
64 (58,70)
0.16
Female
54 (64.3%)
29 (61.7%)
0.85
Never smoker
57 (67.9%)
35 (74.5%)
0.55
BCG scar
170 (83.3%)
40 (85.1%)
1.00
Past medical history
 
 
 
  TB
23 (27.4%)
20 (42.6%)
0.08
  Measles
15 (17.9%)
15 (31.9%)
0.08
  Pertussis
4 (4.8%)
4 (8.5%)
0.46
Comorbidities
 
 
 
  aSinusitis
26 (31.0%)
15 (31.9%)
1.00
  COPD
17 (20.2%)
17 (37.0%)
0.06
  Asthma
3 (3.6%)
1 (2.2%)
1.00
  Gastroesophageal reflux disease
15 (17.9%)
11 (23.4%)
0.50
  Diabetes mellitus
8 (9.5%)
1 (2.1%)
0.16
  Rheumatoid arthritis
9 (10.7%)
2 (4.3%)
0.33
  Cancer
18 (21.4%)
3 (6.4%)
0.03
Symptoms
 
 
 
  Cough
25 (29.8%)
16 (34.0%)
0.70
  bDyspnea
6 (7.1%)
6 (12.8%)
0.40
  Sputum
39 (46.4%)
29 (61.7%)
0.10
  Fever
16 (19.0%)
12 (25.5%)
0.38
  Hemoptysis
19 (22.9%)
17 (36.2%)
0.15
  Post nasal drip
25 (29.8%)
20 (42.6%)
0.18
  Weight loss13 (15.5%)2 (4.3%)0.08

Abbreviations: NTM nontuberculous mycobacteria, BE bronchiectasis, TB tuberculosis, IQR interquartile range, COPD chronic obstructive pulmonary disease.

aDiagnosis of sinusitis was based on self-reporting.

bDyspnea was defined as modified Medical Research Council score ≥ 2.

Baseline characteristics of 84 patients with NTM lung disease and 47 non-NTM BE patients Abbreviations: NTM nontuberculous mycobacteria, BE bronchiectasis, TB tuberculosis, IQR interquartile range, COPD chronic obstructive pulmonary disease. aDiagnosis of sinusitis was based on self-reporting. bDyspnea was defined as modified Medical Research Council score ≥ 2.

Microbiology analysis of patient sputum

Of the 84 patients with NTM lung disease, 47 (60.0%) were infected with species belonging to the Mycobacterium avium complex; 11 (13.1%) were infected with M. abscessus complex species. Multiple NTM species were isolated in 20 (23.8%) patients (Table 2). Bacterial colonization by non-mycobacterial species was observed in 17 (20.2%) and 12 (25.5%) of NTM lung disease and non-NTM BE patients, respectively (P = 1.00). The trend that P. aeruginosa was more commonly isolated from non-NTM BE patients (5 patients, 10.6%) than NTM patients (2 patients, 2.4%) was observed (P = 0.10) (Table 3).
Table 2

Mycobacterial species isolated from 84 patients with NTM lung disease

The number of patients with isolation of single species64/84(76.2%)
Mycobacterium avium complex
47
(60.0%)
    M. avium
 
27
(32.1%)
    M. intracellulare
 
18
(21.4%)
    Mixed
 
2
( 2.4%)
M. abscessus complex
11
(13.1%)
    M. abscessus
 
7
( 8.3%)
    M. massiliense
 
2
( 2.4%)
    Mixed
 
2
( 2.4%)
M. chimaera
1
(1.2%)
M. kansasii
1
(1.2%)
M. fortuitum complex
1
(1.2%)
M. lentiflavum
1
(1.2%)
M. senegalense or conceptionense
1
(1.2%)
Unidentified
1
(1.2%)
The number of patients with isolation of multiple species
20/84
(23.8%)
M. avium complex and others
6
(7.1%)
    M. avium and M. chelonae
 
1
(1.2%)
    M. avium and M. chimaera
 
1
(1.2%)
    M. avium and M. fortiutum
 
1
(1.2%)
    M. avium and M. fortiutum and M. kansasii
 
1
(1.2%)
    M. intracellulare and M. chitae
 
1
(1.2%)
    M. intracellulare and M. fortuitum
 
1
(1.2%)
M. abscessus complex and others
5
(6.0%)
    M. abscessus and M. chelonae
 
1
(1.2%)
    M. abscessus and M. conceptionense
 
1
(1.2%)
    M. abscessus and M. bolletii
 
2
(2.4%)
    M. bolletii and M. lentiflavum
 
1
(1.2%)
M. avium complex and M. abscessus complex
7
(8.3%)
    M. avium and M. absecessus
 
4
(4.8%)
    M. avium and M. massilience
 
1
(1.2%)
    M. avium and M. intracelullare and M. abscessus
 
1
(1.2%)
    M. avium and M. absecessus and M. massiliense
 
1
(1.2%)
Others
2
(2.4%)
    M. chimaera and M. peregrinum
 
1
(1.2%)
    M. gordonae and M. kyorinense 1(1.2%)

Abbreviations: NTM nontuberculous mycobacteria lung disease.

Table 3

Bacterial colonization of respiratory tract among 84 patients with NTM lung diseases and 47 non-NTM BE patients

 
NTM lung diseases patients (N = 84)
Non-NTM BE patients (N = 47)
P value
Any isolates17 (20.2%)12 (25.5%)1.00
Single isolate in one patient
15 
(19.7%)
12 
(26.7%)
0.38
Klebsiella pneumoniae
4
(4.8%)
5
(10.6%)
0.28
Streptococcus pneumoniae
1
(1.2%)
1
(2.1%)
1.00
Streptococcus species, viridans group
1
(1.2%)
0
 
1.00
Methicillin-sensitive Staphylococcus aureus
1
(1.2%)
0
 
1.00
Methicillin-resistant Staphylococcus aureus
2
(2.4%)
0
 
0.54
Pseudomonas fluorescens
1
(1.2%)
0
 
1.00
Pseudomonas putida
1
(1.2%)
0
 
1.00
Pseudomonas aeruginosa
2
(2.4%)
5
(10.6%)
0.10
Aeromonas hydrophila
1
(1.2%)
1
(2.1%)
1.00
Neisseria species
1
(1.2%)
0
 
1.00
Multiple microorganisms
2 
(2.4%)
0 
 
0.54
Methicillin-sensitive Staphylococcus aureus and Pseudomonas fluorescens
1
(1.2%)
0
 
1.00
Methicillin-resistant Staphylococcus aureus and Klebsiellapneumoniae1(1.2%)0 1.00

Abbreviations: NTM nontuberculous mycobacteria, BE bronchiectasis.

Mycobacterial species isolated from 84 patients with NTM lung disease Abbreviations: NTM nontuberculous mycobacteria lung disease. Bacterial colonization of respiratory tract among 84 patients with NTM lung diseases and 47 non-NTM BE patients Abbreviations: NTM nontuberculous mycobacteria, BE bronchiectasis.

Phenotypic characteristics of the participants

No difference in height was observed between NTM lung disease and non-NTM BE patients (160.0 vs. 159.0 cm, P = 0.23). However, patients with NTM lung disease were of lower body weight than those with non-NTM BE (54.0 vs. 55.5 kg, P = 0.04); consequently, the body mass index (BMI) of NTM lung disease patients was also lower than that of non-NTM BE patients (BMI = 20.8 vs. 22.2 kg/m2, P < 0.001). Scoliosis was more common among patients with NTM lung disease than those with non-NTM BE (23.8% vs. 8.5%, P = 0.04) (Table 4).
Table 4

Phenotypic characteristics of 84 patients with NTM lung disease and 47 non-NTM BE patients

 NTM lung disease patients (N = 84)Non-NTM BE patients (N = 47) P value
Height (cm), median (IQR)
160.0 (156.0,168.0)
159.0 (153.0, 167.0)
0.23
Weight (kg), median (IQR)
54.0 (48.3, 60.0)
55.5 (51.0, 63.0)
0.04
BMI (kg/m2), median (IQR)
20.8 (19.3, 22.1)
22.2 (20.5, 24.2)
<.001
Scoliosis, n (%)
20 (23.8%)
4 (8.5%)
0.04
Pectus excavatum*, n (%)6 (7.1%)0 (0.0%)0.09

Abbreviations: NTM nontuberculous mycobacteria, BE bronchiectasis, IQR interquartile range. *Pectus excavatum was defined if the Haller index was > 3.5.

Phenotypic characteristics of 84 patients with NTM lung disease and 47 non-NTM BE patients Abbreviations: NTM nontuberculous mycobacteria, BE bronchiectasis, IQR interquartile range. *Pectus excavatum was defined if the Haller index was > 3.5.

Immunologic parameters of participants

Positive rheumatoid factor was detected more frequently in patients with non-NTM BE than with NTM lung disease (23.4% vs. 6.0%, P = 0.01); however, differences in mean rheumatoid factor levels were not statistically significant. No differences were seen regarding the presence of FANA, nor in FANA titers. Serum immunoglobulin levels were also similar between the two groups. Likewise, the proportion of IGRA-positive patients were similar in NTM lung disease patients and non-NTM BE patients (45.2 vs. 55.3%, P = 0.28) (Table 5).
Table 5

Immunological parameters of 84 patients with NTM lung disease and 47 non-NTM BE patients

 NTM lung disease patients N = 84Non-NTM BE patients N = 47 P value
Positive RF
5 (6.0%)
11 (23.4%)
0.01
RF level (0–9.9 IU/mL)*, median (IQR)
16 (15,92)
18 (15,86)
0.88
Positive FANA
11 (13.1%)
2 (4.3%)
0.14
FANA titer, median (IQR)
40 (40,50)
60 (40,80)
0.74
Positive IGRA
38 (45.2%)
26 (55.3%)
0.28
Patients with low level of immunoglobulins
 
 
 
IgG
(700–1700 mg/dL)*
1 (1.2%)
0 (0%)
1.00
IgA
(90–400 mg/dL)*
3 (3.6%)
0 (0%)
0.55
IgM
(45–230 mg/dL)*
6 (7.1%)
4 (8.5%)
0.75
C3
(70–150 mg/dL)*
1 (1.2%)
1 (2.1%)
1.00
C4(10–35 mg/dL)*1 (1.2%)1 (2.1%)1.00

Abbreviations: FANA fluorescent antinuclear antibody test, IGRA IFN-γ release assay, RF rheumatoid factor, NTM nontuberculous mycobacteria, BE bronchiectasis, IQR interquartile range.

*Normal ranges.

Immunological parameters of 84 patients with NTM lung disease and 47 non-NTM BE patients Abbreviations: FANA fluorescent antinuclear antibody test, IGRA IFN-γ release assay, RF rheumatoid factor, NTM nontuberculous mycobacteria, BE bronchiectasis, IQR interquartile range. *Normal ranges.

Radiological characteristics

The extent of BE was greater in the non-NTM BE group than in nodular bronchiectatic NTM lung disease patients (4 vs. 3 points, P = 0.001). Tubular BE was most common in both groups (Table 6).
Table 6

Radiographic characteristics and extent of lesions of 84 patients with NTM lung disease and 47 non-NTM BE patients

 NTM lung disease patients (N = 84)Non-NTM BE patients (N = 47) P value
Extent of bronchiectasis, median (IQR)
3 (2, 4)
4 (3, 9)
0.001
Type of bronchiectasis
 
 
 
  Tubular
46 (54.8%)
21 (44.7%)
0.28
  Varicose
21 (25.0%)
11 (23.4%)
1.00
  Cystic
17 (20.2%)
15 (31.9%)
0.14
Paranasal sinus
 
 
 
  Normal
62 (73.8%)
33 (70.2%)
0.69
  Mucoepithelial thickening
21 (25.0%)
14 (29.8%)
0.55
  Air-fluid level or total haziness0 (0%)0 (0%) 

Abbreviations: NTM nontuberculous mycobacteria, BE bronchiectasis, IQR interquartile range.

†Extent of bronchiectasis was scored in each 6 lobe according to involved percentage of bronchiectatic bronchi. Extent scores range from 0 to 18; 0 if less than 25%, 1 if 25 ~ 49%, 2 if 50 ~ 74%, 3 if 75% or more.

‡Classified based on main lesion.

Radiographic characteristics and extent of lesions of 84 patients with NTM lung disease and 47 non-NTM BE patients Abbreviations: NTM nontuberculous mycobacteria, BE bronchiectasis, IQR interquartile range. †Extent of bronchiectasis was scored in each 6 lobe according to involved percentage of bronchiectatic bronchi. Extent scores range from 0 to 18; 0 if less than 25%, 1 if 25 ~ 49%, 2 if 50 ~ 74%, 3 if 75% or more. ‡Classified based on main lesion.

Pulmonary function

No differences in FVC were observed between NTM lung disease patients and non-NTM BE patients in terms of either absolute volume (2.8 vs. 2.7 L, P = 0.13) although percentage of predicted volume were smaller among non-NTM BE patients (94% vs. 87%, P = 0.02). Both absolute volume of FEV1 (2.1 vs. 1.8 L, P = 0.001) and percentage of predicted volume (101% vs. 86%, P = 0.001) were smaller among non-NTM BE patients. However, the proportion of patients who met criteria for chronic obstructive pulmonary disease was not different between two groups (13.6% vs. 23.9%, P = 0.15) (Table 7).
Table 7

Pulmonary function of 81 patients with NTM lung disease and 46 non-NTM BE patients*

Number of patientsNTM lung disease patients (N = 81)NonNTM BE patients (N = 46) P value
FVC, L
2.8 (2.3,3.4)
2.7 (2.2,3.2)
0.13
  % pred.
94 (81,104)
87 (76,97)
0.02
FEV1, L
2.1 (1.8,2.6)
1.8 (1.4,2.2.3)
0.001
  % pred.
101 (85,112)
86 (67,99)
0.001
FEV1/FVC%
78 (72,82)
73 (65,81)
0.01
Patterns of ventilation
 
 
 
  Normal
52 (64.2%)
20 (43.5%)
0.03
  Restrictive
16 (19.8%)
10 (21.7%)
0.82
  Obstructive
11 (13.6%)
11 (23.9%)
0.15
  Mixed2 (2.5%)5 (10.9%)0.10

*The results of the pulmonary function test could not be performed because of bloody sputum or patients’ refusal in three NTM lung disease patients and one non-NTM-BE patient.

Pulmonary function of 81 patients with NTM lung disease and 46 non-NTM BE patients* *The results of the pulmonary function test could not be performed because of bloody sputum or patients’ refusal in three NTM lung disease patients and one non-NTM-BE patient.

Quality of life and emotional status

Median St. George’s respiratory questionnaire scores were similar between the two groups (19.5 vs.18.1, P = 0.34). Twenty patients (23.8%) with NTM lung disease and 10 patients (21.3%) with non-NTM BE reported anxiety (P = 0.83). Twenty-three 23 patients (27.4%) with NTM lung disease and 10 patients (21.3%) with non-NTM BE reported symptoms of depression (P = 0.53).

Discussion

Through this prospective study, we collected phenotypic, immunologic, and other clinical data from patients with nodular BE type NTM lung disease and compared them with those of BE patients. These data confirmed several known characteristics of patients with NTM lung disease in the Korean population. The phenotypic characteristics of patients with NTM lung disease in this study were similar to those described in previous reports [3,4,13,14]. Patients with NTM lung disease were leaner than non-NTM BE patients in our study. Although the underlying mechanism for the association between NTM lung disease and low BMI is not well understood, decreased leptin and increased adiponectin, and/or decreased estrogen in older women with low BMI may account for the increased susceptibility of these individuals to NTM infections [3]. In addition to low BMI, scoliosis and pectus excavatum are also frequently observed among NTM lung disease; a higher rate of scoliosis in patients with NTM lung disease was also seen in our study. These skeletal abnormalities may be indicative of an underlying genetic predisposition, though a precise mechanism linking the two has not been proposed [15]. M. avium complex and M. abscessus were the most common organisms isolated, consistent with a previous report on Korean patients with NTM lung disease [16]. Frequent isolation of M. abscessus is one of the characteristics of Korean patients that differ from patients from other countries [4]. Mixed infection by two or more NTM species was observed in 23.8% (20/84) of our patients; this observation confirmed our previous retrospective study showing high rates of mixed NTM infections [17]. Further examination will be necessary to determine the clinical significance of these mixed NTM infections. We assessed several immunological markers, including FANA, rheumatoid factor, and serum immunoglobulins, and compared them with those of BE patients. Although most immunological markers were similar between the NTM lung disease and non-NTM BE groups, rheumatoid factor was found more commonly in patients with non-NTM BE. Given that the prevalence of rheumatoid arthritis and FANA were similar in both groups, the higher frequency of rheumatoid factor among patients with BE may be interpreted as a false positive. Various clinical settings have been shown to cause false positive results for rheumatoid factor [18]. NTM lung disease patients in our cohort were less likely to harbor P. aeruginosa than BE patients. Previous studies have also reported lower incidence of P. aeruginosa in BE or cystic fibrosis patients with NTM colonization. The underlying mechanism driving this phenomenon is not yet understood, but the observation that decontamination of P. aeruginosa yielded the cultivation of NTM colonization suggests a level of antagonism between P. aeruginosa and NTM [8,19]–[22]. A considerable number of NTM lung disease and non-NTM BE patients in our study reported feelings of anxiety (23.8% and 21.3%, respectively) as well as depression (27.4% and 21.3%, respectively). Given that the lifetime prevalence of depression and anxiety disorders in South Korea are 5.6% and 6.9%, respectively [23], rates reported here appear significantly higher than those in the general population. A similar study conducted in the United States showed that 20% of BE patients had elevated depression-related scores and 38% had elevated anxiety-related scores [24]. Consistently higher rates of depression and anxiety among NTM lung disease patients and non-NTM BE patients may stem from increased respiratory symptoms as well as other comorbidities.

Conclusions

In conclusion, the characteristics of Korean NTM lung disease patients in this study were similar to those of patients in other countries. The fact that some phenotypic and clinical characteristics of NTM lung disease patients were different from those of non-NTM BE patients suggests differences in the immunopathogenesis of NTM lung disease and non-NTM BE.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

Study concept and design: JJY. Acquisition of data: ARL, MWS, SAK, MK, KOC. Analysis and interpretation of data: ARL, JL, SMC, JJY. Drafting of the manuscript: ARL. Critical revision of the manuscript for important intellectual content: ARL, JL, SMC, MOS, JJY. Statistical analysis: ARL, JJY. Study supervision: JJY. All authors read and approved the final manuscript.

Pre-publication history

The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2334/13/558/prepub
  23 in total

1.  Positive anti-cyclic citrullinated proteins and rheumatoid factor during active lung tuberculosis.

Authors:  O Elkayam; R Segal; M Lidgi; D Caspi
Journal:  Ann Rheum Dis       Date:  2005-12-16       Impact factor: 19.103

2.  Chronic sputum production: correlations between clinical features and findings on high resolution computed tomographic scanning of the chest.

Authors:  I E Smith; E Jurriaans; S Diederich; N Ali; J M Shneerson; C D Flower
Journal:  Thorax       Date:  1996-09       Impact factor: 9.139

3.  Nontuberculous mycobacteria in bronchiectasis: Prevalence and patient characteristics.

Authors:  S J Fowler; J French; N J Screaton; J Foweraker; A Condliffe; C S Haworth; A R Exley; D Bilton
Journal:  Eur Respir J       Date:  2006-06-28       Impact factor: 16.671

Review 4.  Mycobacterium abscessus and other nontuberculous mycobacteria: evolving respiratory pathogens in cystic fibrosis: a case report and review.

Authors:  Don Hayes
Journal:  South Med J       Date:  2005-06       Impact factor: 0.954

5.  Recovery of mycobacteria from patients with cystic fibrosis.

Authors:  F C Bange; P Kirschner; E C Böttger
Journal:  J Clin Microbiol       Date:  1999-11       Impact factor: 5.948

6.  Depression and anxiety symptoms in bronchiectasis: associations with health-related quality of life.

Authors:  Casilda Olveira; Gabriel Olveira; Inmaculada Gaspar; Antonio Dorado; Ivette Cruz; Federico Soriguer; Alexandra L Quittner; Francisco Espildora
Journal:  Qual Life Res       Date:  2012-04-29       Impact factor: 4.147

7.  Non-tuberculous mycobacteria: patterns of isolation. A multi-country retrospective survey.

Authors:  N Martín-Casabona; A R Bahrmand; J Bennedsen; V Ostergaard Thomsen; M Curcio; M Fauville-Dufaux; K Feldman; M Havelkova; M L Katila; K Köksalan; M F Pereira; F Rodrigues; G E Pfyffer; F Portaels; J Rosselló Urgell; S Rüsch-Gerdes; E Tortoli; V Vincent; B Watt
Journal:  Int J Tuberc Lung Dis       Date:  2004-10       Impact factor: 2.373

8.  Non-tuberculous mycobacteria in patients with bronchiectasis.

Authors:  M Wickremasinghe; L J Ozerovitch; G Davies; T Wodehouse; M V Chadwick; S Abdallah; P Shah; R Wilson
Journal:  Thorax       Date:  2005-10-14       Impact factor: 9.139

Review 9.  Diagnosis and treatment of nontuberculous mycobacterial pulmonary diseases: a Korean perspective.

Authors:  Won-Jung Koh; O Jung Kwon; Kyung Soo Lee
Journal:  J Korean Med Sci       Date:  2005-12       Impact factor: 2.153

10.  New strains of bacteria and exacerbations of chronic obstructive pulmonary disease.

Authors:  Sanjay Sethi; Nancy Evans; Brydon J B Grant; Timothy F Murphy
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

View more
  12 in total

Review 1.  Nontuberculous mycobacteria in cystic fibrosis and non-cystic fibrosis bronchiectasis.

Authors:  In Kwon Park; Kenneth N Olivier
Journal:  Semin Respir Crit Care Med       Date:  2015-03-31       Impact factor: 3.119

Review 2.  [Nontuberculous mycobacteria in sputum : Recommendations for diagnosis and treatment].

Authors:  J Rademacher
Journal:  Internist (Berl)       Date:  2017-11       Impact factor: 0.743

3.  Non-tuberculous mycobacterial lung disease: diagnosis based on computed tomography of the chest.

Authors:  Nakwon Kwak; Chang Hyun Lee; Hyun-Ju Lee; Young Ae Kang; Jae Ho Lee; Sung Koo Han; Jae-Joon Yim
Journal:  Eur Radiol       Date:  2016-03-05       Impact factor: 5.315

Review 4.  Respiratory review of 2014: tuberculosis and nontuberculous mycobacterial pulmonary disease.

Authors:  Cheol Kyu Park; Yong Soo Kwon
Journal:  Tuberc Respir Dis (Seoul)       Date:  2014-10-31

Review 5.  Diagnosis of pulmonary tuberculosis and nontuberculous mycobacterial lung disease in Korea.

Authors:  Yong Soo Kwon; Won-Jung Koh
Journal:  Tuberc Respir Dis (Seoul)       Date:  2014-07-31

6.  Characteristics associated with progression in patients with of nontuberculous mycobacterial lung disease : a prospective cohort study.

Authors:  Soo Jung Kim; Soon Ho Yoon; Sun Mi Choi; Jinwoo Lee; Chang-Hoon Lee; Sung Koo Han; Jae-Joon Yim
Journal:  BMC Pulm Med       Date:  2017-01-05       Impact factor: 3.317

7.  Effects of pain on depression, sleep, exercise tolerance, and quality of life in patients with nontuberculous mycobacterial pulmonary disease.

Authors:  Kosuke Mori; Mitsuru Tabusadani; Kazumasa Yamane; Satoshi Takao; Yuki Kuroyama; Yusuke Matsumura; Kazuki Ono; Kazuma Kawahara; Shunya Omatsu; Keiji Fujiwara; Koji Furuuchi; Kozo Morimoto; Hiroshi Kimura; Hideaki Senjyu
Journal:  Medicine (Baltimore)       Date:  2021-06-11       Impact factor: 1.817

8.  Nontuberculous mycobacterial infection is associated with increased respiratory failure: a nationwide cohort study.

Authors:  Jun-Jun Yeh; Yu-Chiao Wang; Cheng-Li Lin; Christine Yi-Ting Chou; Ting-Chun Yeh; Bing-Tsang Wu; Fung-Chang Sung; Chia-Hung Kao
Journal:  PLoS One       Date:  2014-06-11       Impact factor: 3.240

Review 9.  Diagnosis and Treatment of Nontuberculous Mycobacterial Lung Disease.

Authors:  Yong-Soo Kwon; Won-Jung Koh
Journal:  J Korean Med Sci       Date:  2016-03-22       Impact factor: 2.153

10.  Role of ethambutol and rifampicin in the treatment of Mycobacterium avium complex pulmonary disease.

Authors:  Hyung-Jun Kim; Jong Sik Lee; Nakwon Kwak; Jaeyoung Cho; Chang-Hoon Lee; Sung Koo Han; Jae-Joon Yim
Journal:  BMC Pulm Med       Date:  2019-11-11       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.